Investigating Tiobec® 400's efficacy in alleviating Restless Legs Syndrome symptoms sheds light on promising therapeutic avenues.

Restless legs syndrome, also known as Willis-Ekbom disease, is a neurological disorder characterised by uncomfortable sensations in the legs and an urge to move them. In Spain, its prevalence range is estimated to be between 11.6% - 19.5% in adults, but it is difficult to know due to underdiagnosis. Alpha-lipoic acid (ALA) and B vitamins have emerged as potential treatments due to their roles in reducing oxidative stress and associated vitamin deficiencies. The Tiobec® 400 (T400) supplement combines ALA, B vitamins, E, and C, and its efficacy and safety in alleviating RLS symptoms, along with its impact on anthropometric measures, are under investigation. This study aims to explore therapeutic options for managing RLS, with promising results.

Inclusion Criteria:

• Participants must be a minimum of 18 years of age.
• They must have a primary diagnosis of RLS without prior therapeutic interventions for the ailment.
• They need to provide explicit consent via an informed consent document.

Exclusion Criteria:

• Patients diagnosed with pathologies other than RLS that affect sleep quality.
• Those with persistent renal diseases or any other chronic, severe medical condition.

The data will be collected from patients who meet the selection criteria.